Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharma save search
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
Published: 2024-03-12 (Crawled : 12:30) - globenewswire.com
INZY | $4.485 -2.07% 88K
|
Health Technology
|
| O: -0.7%
H: 1.75%
C: 0.35%
pharma business year financial results
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
NAMS | $19.97 2.73% 23K
|
n/a
|
| O: -0.14%
H: 14.78%
C: 12.05%
first pharma trial
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
LTRN | $5.52 -4.33% 110K
|
Health Technology
|
| O: -2.06%
H: 0.74%
C: -21.98%
pharma report year financial results
Vaccine research market size to grow at a CAGR of 9.88% from 2022 to 2027, Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, more to emerge as key players, Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CMXHF | $172.54 50
|
n/a
|
| O: 0.41%
H: 0.0%
C: 0.0%
CSLLY | $86.918 60K
|
n/a
|
| O: -4.92%
H: 3.76%
C: 3.44%
GLAXF | $20.2 510
|
Health Technology
|
| O: -3.4%
H: 1.49%
C: 1.49%
AZNCF | $138.24 800
|
Health Technology
|
| O: 1.55%
H: 0.82%
C: 0.16%
ALPMY | $9.47 520K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
GSK | $39.685 1.06% 380K
|
Health Technology
|
| O: -0.6%
H: 0.19%
C: 0.09%
ABT | News | $107.24 1.87% 2M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
AZN | $68.545 0.27% 1.2M
|
Health Technology
|
| O: 1.08%
H: 0.82%
C: 0.67%
pharma vaccine astrazeneca research key market
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Published: 2024-03-08 (Crawled : 16:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 8, 2024
Published: 2024-03-08 (Crawled : 14:00) - biospace.com/
URGN | $13.56 -4.91% 59K
|
Health Technology
|
| O: 0.33%
H: 2.93%
C: -0.55%
pharma nasdaq grants
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
Published: 2024-03-08 (Crawled : 13:00) - globenewswire.com
OCUP | $1.69 1.2% 27K
|
Health Technology
|
| O: -1.26%
H: 0.0%
C: -15.32%
pharma year update financial results
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
ATHA | $2.14 3.88% 68K
|
Health Technology
|
| O: 0.0%
H: 1.45%
C: -13.73%
fosgonimeton pharma conference alzheimer’s international preclinical parkinson’s potential
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
LUMO | News | $2.62 790
|
Health Technology
|
| O: -1.65%
H: 4.03%
C: 2.01%
pharma year update financial results
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
EVOK | $0.539 12.57% 470
|
Health Technology
|
| O: 1.29%
H: 2.27%
C: -0.57%
pharma report year results
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
Published: 2024-03-06 (Crawled : 12:00) - globenewswire.com
HOOK | $0.7649 88K
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: -4.27%
pharma conference biopharma global
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock - March 06, 2024
Published: 2024-03-06 (Crawled : 12:00) - biospace.com/
BBIO | $24.895 -0.22% 570K
|
Health Technology
|
| O: 2.36%
H: 2.34%
C: -2.81%
pharma offering
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
Published: 2024-03-06 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 0.0%
H: 0.8%
C: 0.8%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
IPHA | $2.35 2.3K
|
Health Technology
|
| O: 0.78%
H: 1.93%
C: 0.97%
iph45 pharma drug antibody preclinical
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
Published: 2024-03-06 (Crawled : 05:00) - bridgebio.com
BBIO | $24.895 -0.22% 570K
|
Health Technology
|
| O: 2.36%
H: 2.34%
C: -2.81%
pharma offering
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Published: 2024-03-05 (Crawled : 21:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
| Email alert
Add to watchlist
pharma employee
FSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum
Published: 2024-03-05 (Crawled : 14:00) - biospace.com/
HUGE | $0.6167 1.22% 29K
|
Process Industries
|
| O: -13.48%
H: 15.52%
C: 12.05%
pharma positive sclerosis treatment research results lucid-21-302 study
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
Published: 2024-03-04 (Crawled : 21:00) - globenewswire.com
BBIO | $24.895 -0.22% 570K
|
Health Technology
|
| O: -2.32%
H: 0.62%
C: -6.34%
pharma offering
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
ASND | $142.8 1.36% 55K
|
Health Technology
|
| O: 1.0%
H: 0.0%
C: -3.9%
pharma conference biopharma global
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
Published: 2024-03-04 (Crawled : 13:30) - biospace.com/
URGN | $13.56 -4.91% 59K
|
Health Technology
|
| O: 0.73%
H: 4.08%
C: 2.91%
pharma report financial results
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
ZCMD | $1.98 36.55% 27M
|
Commercial Services
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.304 25.57% 47M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.